MPN-343: The BET Inhibitor Pelabresib Decreases Inflammatory Cytokines, Improves Bone Marrow Fibrosis and Function, and Demonstrates Clinical Response Irrespective of Mutation Status in Myelofibrosis Patients in the Phase 2 MANIFEST Trial

Oksana Zavidij, Patrick Trojer, Jike Cui et al.|Clinical Lymphoma Myeloma & Leukemia|2021

Cited by 4